Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cyclerion Therapeutics, Inc. - Common Stock (NQ:CYCN)

3.278 +0.121 (+3.83%)
Streaming Delayed Price Updated: 3:51 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclerion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning! 
Via InvestorPlace
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million. 
Via Benzinga
Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction
Via Benzinga
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 10.8% to $0.39 during Monday's after-market session. The market value of their outstanding shares is at $16.8 million. 
Via Benzinga
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Avenue Therapeutics Is Trading Lower By 59%; Here Are 31 Stocks Moving Premarket
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares rose 42.3% to $11.36 in pre-market trading after jumping 83% on Thursday. 
Via Benzinga
Dow Dips Over 300 Points; Provention Bio Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 300 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
Why Cyclerion Therapeutics Stock Is Getting Hammered
Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares are trading lower by 43.33% to $0.53 during Thursday's trading session after the company announced a mitochondrial disease-focused strategy. The plan... 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
Nasdaq Edges Higher; AngioDynamics Shares Plummet
U.S. stocks pared losses midway through trading, with the Nasdaq Composite turning higher on Thursday. 
Via Benzinga
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
Via Benzinga
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.